Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients

Table 1 Basic demographic data and underlying liver status in both groups

	Group I	Group II	P value
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
Age (mean ± SD)	60.17 ± 7.75	59.84 ± 9.12	0.70
Gender			0.33
Female	36 (23.8)	97 (28.0)
Male	115 (76.2)	249 (72.0)
Residence			0.28
Rural	131 (86.8)	287 (82.9)
Urban	20 (13.2)	59 (17.1)
BCLC			< 0.001a
0	5 (3.3)	15 (4.3)
A	47 (31.1)	134 (38.7)
B	17 (11.3)	68 (19.7)
C	49 (32.5)	50 (14.5)
D	33 (21.9)	79 (22.8)
MELD (mean ± SD)	14.35 ± 5.041	36.10 ± 30.22	< 0.001a
CTP score			0.04
A	50 (33.1)	88 (25.4)
B	65(43.0)	138 (39.9)
C	36 (23.8)	120 (34.7)
FIB4			< 0.001c
mean ± SD	3.25 ± 9.87	7.11 ± 7.68
Median	0.023	4.49
IQR	4.51	6.2
HCC detection time after stop of DAAS	Range: 1-72 moMedian: 8 mo	-	-

^aP < 0.05.

^cP < 0.001.

HCC: Hepatocellular carcinoma; MELD: Model for end stage liver disease; CTP: Child Turcotte-pough; BCLC: Barcelona cancer liver clinic.